高端医疗器械是"国之重器"，被视为国家制造能力和科技发展水平的重要标志。深圳是国内高端医疗器 械产业的集聚地之一，不仅诞生了迈瑞医疗、华大基因、新产业等进入全球医疗器械百强的知名公司， 还产生了诸多细分领域的隐形冠军。 深圳市医疗器械行业协会数据显示，2023年，深圳医疗器械产值990亿元，占全国大概10%，出口占比 也近10%，多年位居全国中大城市首位。根据规划，全市医疗器械2025年营业收入将达到2000亿元。 深圳医疗器械产业何以聚集，为何变强？集群内的产业链、创新链、资金链又如何有效互动？证券时报 记者走进产业一线，一探究竟。 当脑机接口遇上先进制造 "请闭眼，放松。""请睁眼，并想象手握拳。" 在香港中文大学（深圳）医学院附属第三医院康复医学科，徐磊（化名）戴着黑色电极头套，右手插入 一只金色的"机械手套"做康复训练。他因为中风偏瘫导致手部功能障碍，手指一度无法动弹，经过一个 多月的训练后，已经能够完成一些抓握动作。 医院康复科主任王本国对证券时报记者介绍，当大脑"司令部"受损，患者可以通过运动想象和机械力的 刺激，借助脑机接口机器人，让大脑的神经轴突重新生长，形成新的反射，这便是"机械手套"的工作 ...

证券时报记者 潘玉蓉 深圳医疗器械企业能够长成千亿产业集群，既源自于国家对科技自立自强的时代要求，又得益于深圳制造业根基 深厚的产业沃土，更离不开企业家们锐意进取的奋斗精神、政府不遗余力地资源统筹，可谓是天时、地利、人和 的结果。这是记者在调研深圳医疗器械产业的过程中最大的感受。 相比德国、美国早在19世纪就开始深入研究医疗技术领域，我国的高端医疗器械起步晚，技术沉淀不强，关键设 备长期依赖进口，"独立自主"和"国产替代"始终是驱动产业发展的核心动能。迈瑞医疗、华大基因、理邦仪器等大 型医疗器械公司，均是抓住这一时代机遇得以成长为行业领军力量。这可以称之为"天时"。 记者在走访中发现，大量医疗器械企业选择来到深圳、扎根深圳，与这里的产业基础分不开。得益于上下游完善 的配套，睿瀚医疗将脑机接口产品成功落地，爱康生物在细分领域走出一条"先做精、再做强"的道路。医疗器械 与电子行业深度融合，与新能源、智能制造等行业的联动也十分紧密，而这些都是深圳的优势产业。在产业"卡脖 子"的地方，国家创新平台与企业一起联合攻关；在竞争性领域，知识产权被高度重视，企业做研发劲头十足。一 款填补市场缺口的新产品，让整个产业链受益，这 ...

Group 1 - The core viewpoint of the article highlights the rise of Mindray Medical as a symbol of the Shenzhen medical device industry's transformation from non-existence to a global leader in medical devices and solutions [1] - Mindray Medical has significantly impacted the supply chain by promoting the localization of core components, with over 80% of its first-tier suppliers being domestic, and collaborating with more than 1,500 suppliers across various sectors [1] - During the surge in demand for ventilators in 2020, Mindray Medical increased its procurement of domestic components and worked closely with suppliers to enhance production capacity and establish quality control standards [1] Group 2 - Mindray Medical is driving the high-end standardization of domestic medical devices, with a reputation for rigorous quality testing, which has elevated the quality control standards across the industry [2] - The company's products are now available in over 190 countries, with a market share in the top three for key products like monitors, anesthesia machines, and ventilators, and international revenue contributing approximately 45% of total income [2] - Mindray Medical's internationalization strategy includes utilizing local talent, with nearly 80% of overseas key employees required to regularly visit the Shenzhen headquarters for knowledge exchange [3] Group 3 - The company has established a robust overseas talent management system, integrating local knowledge with its corporate culture to enhance cohesion and operational effectiveness [3] - Over 90% of Mindray Medical's 3,000 overseas employees are local hires, demonstrating the company's commitment to local integration in global markets [3]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][35] Core Views - The company is expected to see a significant improvement in domestic business starting from the third quarter of 2025, following a period of adjustment due to various pressures [9][33] - The company has strong R&D capabilities and a digital transformation strategy that integrates "equipment + IT + AI," which is anticipated to redefine the global positioning of Chinese medical devices [35] Financial Performance Summary - In 2024, the company achieved revenue of 36.726 billion (up 5.1%) and a net profit of 11.668 billion (up 0.7%). However, Q4 2024 saw a revenue decline of 5.1% and a net profit drop of 41.0% [9][12] - For Q1 2025, the company reported revenue of 8.237 billion (down 12.1%) and a net profit of 2.629 billion (down 16.8%), but with a notable quarter-on-quarter improvement [9][33] - The company’s gross profit margin for 2024 was 63.11%, with a slight decrease from the previous year, while the net profit margin was 31.97% [25][35] Business Segment Performance - The in-vitro diagnostics segment became the largest business unit, generating revenue of 13.765 billion (up 10.82%), with international sales growing over 30% [2][17] - The life information and support segment reported revenue of 13.557 billion (down 11.1%), while the minimally invasive surgery business grew over 30% [2][12] - The medical imaging segment achieved revenue of 7.498 billion (up 6.60%), with a market share exceeding 30% in domestic ultrasound [18][24] Future Projections - The company has revised its profit forecasts for 2025-2026 downwards but has introduced a new forecast for 2027, expecting net profits of 12.411 billion, 14.103 billion, and 16.188 billion for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 6.4%, 13.6%, and 14.8% [33][35] - The current price-to-earnings (PE) ratios are projected at 22.7, 19.9, and 17.4 for 2025, 2026, and 2027 respectively [35]

Investment Rating - The investment rating for the company is "Outperform the Market" [6][35]. Core Views - The company is expected to see a significant improvement in domestic business performance starting from the third quarter of 2025, following a period of adjustment due to various pressures [9][33]. - The company has strong R&D capabilities and is positioned as a leading domestic medical device manufacturer, with a digital transformation strategy that integrates "equipment + IT + AI" [3][35]. Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 36.726 billion yuan (+5.1%) and a net profit of 11.668 billion yuan (+0.7%). However, the fourth quarter saw a revenue decline of 5.1% and a net profit drop of 41.0% [9][3]. - For Q1 2025, the company reported a revenue of 8.237 billion yuan (-12.1%) and a net profit of 2.629 billion yuan (-16.8%), showing a significant quarter-on-quarter improvement [9][3]. Business Segments - The in-vitro diagnostics segment became the largest business unit, generating 13.765 billion yuan (+10.82%), with international sales growing over 30% [2][17]. - The life information and support segment generated 13.557 billion yuan (-11.1%), while the medical imaging segment achieved a revenue of 7.498 billion yuan (+6.60%) [2][18]. Profitability Metrics - The gross profit margin for 2024 was 63.11%, a decrease of 1.07 percentage points year-on-year, primarily due to pressures from the life information and support and in-vitro diagnostics products [3][25]. - The net profit margin for Q1 2025 improved to 32.69%, despite a year-on-year decline [3][25]. Future Projections - The company has revised its profit forecasts for 2025-2026 downwards but introduced a new forecast for 2027, expecting net profits of 12.411 billion yuan, 14.103 billion yuan, and 16.188 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 6.4%, 13.6%, and 14.8% [3][35]. - The current price-to-earnings (PE) ratios are projected to be 22.7, 19.9, and 17.4 for 2025, 2026, and 2027 respectively [3][35].

JohnV.Oyler（欧雷强） ，1968年出生，百济神州联合创始人，自2010年起一直担任公司执行董事、董事会 主席兼首席执行官。于1990年获得麻省理工学院的理学学士学位，于1996年获得斯坦福大学的工商管理硕 士学位。欧雷强以管理顾问职务在麦肯锡公司（McKinsey&Company）开始其职业生涯。1997年至1998 年，欧雷强担任GentaIncorporated联席首席执行官，该公司为一家在纳斯达克交易所上市的以肿瘤为重点的 生物制药企业。1998年至2002年，欧雷强创立Telephia,Inc.并担任总裁，该公司于2007年被尼尔森公司 （The Nielsen Company）收购。2002年至2004年，欧雷强担任Galenea Corp的首席执行官，该公司为一家致 力于开发新的中枢神经系统疾病治疗方法的生物制药企业。2005年至2009年，欧雷强担任BioDuro,LLC的总 裁兼首席执行官，该公司为一家药品开发外包公司，后被Pharmaceutical Product Development Inc.收购。 2019年，欧雷强正式入选生物技术产业协会（BIO）董事会及其卫生部门理事 ...

保险 中国太保 队 中国人保 中国平安 01 3710.39亿市值 3306.51亿市值 9913.65亿市值 11.90亿成交额 20.47亿成交额 18.79亿成交额 34.37 8.39 54.44 -0.36(-1.04%) -0.25(-0.46%) +0.15(+1.82%) 酸酒行业 贵州茅台 山西汾酒 五粮液 20559.69亿市值 5212.22亿市值 2574.61亿市值 25.10亿成交额 12.64亿成交额 4.33亿成交额 211.04 134.28 1636.66 +1.67(+0.10%) +0.34(+0.16%) -0.98(-0.72%) 半导体 北方华创 寒武纪-U 海光信息 HYGON 2313.03亿市值 2814.87亿市值 3307.53亿市值 6.62亿成交额 5.68亿成交额 14.31亿成交额 142.30 433.01 674.29 -9.70(-1.42%) -1.92(-1.33%) -3.93(-0.90%) 汽车整车 铁路公路 比亚迪 长城汽车 京沪高铁 11581.58亿市值 2019.19亿市值 2941.48亿市值 51.73亿成交额 3.0 ...

证券研究报告 行业深度 医疗器械 AI 医疗重构诊疗流程，效率与市场增长下的投资机会 | 2025 年 05 月 13 日 | | | --- | --- | | 评级 | 领先大市 | 评级变动： 维持 行业涨跌幅比较 % 1M 3M 12M 医疗器械 3.41 -2.04 -11.64 沪深 300 3.89 -0.60 6.27 -25% -15% -5% 5% 15% 25% 2024-05 2024-08 2024-11 2025-02 2025-05 医疗器械 沪深300 龙靖宁 分析师 执业证书编号:S0530523120001 longjingning@hnchasing.com 相关报告 1 医疗器械行业 4 月报：国家药监局发布征求意 见稿，全力支持高端医疗器械重大创新 2025-04-15 2 医疗器械行业 3 月报：DeepSeek 加速 AI 医疗 落地，建议关注相关企业投资机遇 2025-03-12 3 医疗器械行业 2 月报：国务院创新药械支持文 件出台，政策红利有望进一步释放 2025-02-10 | 重点股票 | 2024A | | 2025E | | 2026E | | 评 ...

内容概况：CT设备通过球管发出X射线，X射线穿透人体组织后被探测器接收并转换为数字信号，经计 算机变换处理后形成被检查部位的断面或立体图像，从而发现人体组织或器官病变。CT设备具有扫描 时间快、图像空间分辨率高、图像清晰的特点，能够为体检、诊断及治疗提供所需信息，可用于多种疾 病的检查。近年来，随着技术的进步，我国CT设备在心脏扫描、肺部筛查和儿科疾病检查等功能运用 方面持续突破。与此同时，我国人口老龄化、慢性病患病人数增加，社会对CT检查的临床需求不断增 长，CT设备在疾病筛查和诊断中的优势以及配备的必要性更加凸显，各级医疗机构对CT设备的采购需 求持续增长促使我国CT设备市场规模呈现快速增长的态势。数据显示，2024年中国CT设备市场规模约 为255亿元。随着我国医疗健康行业投入增加，分级诊疗的推行，未来CT设备市场将保持高速发展。 相关上市企业：联影医疗（688271）、新华医疗（600587）、万东医疗（600055）、美亚光电 （002690）、国力股份（688103）、永新光学（603297）、皖仪科技（688600）、奕瑞科技 （688301）、广信科技（874094）、迈瑞医疗（300760） ...

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight decline of 0.23% recently, reflecting a mixed performance over different time frames, with a year-to-date decrease of 0.88% [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,568.19 points with a trading volume of 15.409 billion yuan [1]. - Over the past month, the index has increased by 2.13%, while it has decreased by 5.63% over the last three months [1]. - The index has a year-to-date decline of 0.88% [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.73%), Aier Eye Hospital (8.29%), and United Imaging Healthcare (7.73%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (61.00%) and the Shanghai Stock Exchange (39.00%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern Asset Management's various funds and Tianhong's ETF [2].